Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies ; volume:99 ; number:10 ; day:27 ; month:8 ; year:2020 ; pages:2215-2229 ; date:10.2020
Annals of hematology ; 99, Heft 10 (27.8.2020), 2215-2229, 10.2020
- Creator
-
Viardot, Andreas
Locatelli, Franco
Stieglmaier, Julia
Zaman, Faraz
Jabbour, Elias
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-020-04221-0
- URN
-
urn:nbn:de:101:1-2020102918354888141262
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Viardot, Andreas
- Locatelli, Franco
- Stieglmaier, Julia
- Zaman, Faraz
- Jabbour, Elias
- SpringerLink (Online service)
Other Objects (12)
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan